Back

Helen E Heslop

Helen E Heslop is affiliated with Baylor College of Medicine.[1]She specializes in medicine.[1]

Helen Heslop, M.D., D.Sc., is professor of Medicine and Pediatrics at Baylor College of Medicine, and the director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital.[2]She is also associate director for Clinical Research at the Dan L Duncan Cancer Center.[2]She has extensive experience in developing and conducting transplant studies and cell and gene therapy studies.[2]She served as president of the American Society of Blood and Marrow Transplantation in 2008, and is now president of the Foundation for Accreditation of Cell Therapy.[1]She is one of the field's best-known experts in developing methods and procedures for generating cytotoxic T cell lymphocytes that can be used to drive life-changing therapeutic results for patients.[3]Her work focuses on translational research using adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy.[4]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Helen E Heslop on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Center for Cell and Gene Therapy

Employer

  • 1

    Event

  • 172

    Mentions

  • 51

    Docs

Recent events

Kiadis Pharma announces formation of renowned Scientific Advisory Board

Dr. Fehniger received his MD/PhD in Medicine/Immunology from The Ohio State University College of Medicine and completed residency and fellowship training at Washington University School of Medicine. Helen Heslop, MD, DScHelen Heslop, MD, DSc, is a physician-scientist at Baylor College of Medicine engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy.[5]

10/22/2019

Event Date